A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination with Immune Therapeutic Agents in Adult Subjects with Advanced Solid Tumors
||Male and Female Patients
|U.S. Govt. ID:
||Richard Carvajal, MD: 646-317-6344 / firstname.lastname@example.org
The main purpose of this study is to determine the best dose of MEDI0562 in combination with durvalumab, and MEDI0562 in combination with tremelimumab, that is safe and tolerable in subjects with advanced solid tumors.
This study is closed
Richard Carvajal, MD
|Have you been diagnosed with a solid tumor?